Century Therapeutics
IPSC
54 hedge funds and large institutions have $209M invested in Century Therapeutics in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 10 closing their positions.
14% more capital invested
Capital invested by funds: $183M → $209M (+$25.9M)
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
1.14% less ownership
Funds ownership: 36.97% → 35.83% (-1.1%)
4% less funds holding
Funds holding: 56 → 54 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.62M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$3.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.7M |
| 4 |
BlackRock
New York
|
+$1.08M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$6.36M |
| 2 |
Morgan Stanley
New York
|
-$4.13M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.67M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.33M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.75M |
IPSC Hedge Fund Activity: Q3 2022 in Review
54 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q3 2022, worth a combined $209M — up 14% from $183M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of IPSC and 8 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 18 added.
The largest buyer was Avidity Partners Management, adding an estimated $4.62M. The largest seller was RA Capital Management, exiting entirely with an estimated $6.36M sold.
- 54 institutional investors held Century Therapeutics (IPSC) as of Q3 2022, down from 56 in Q2 2022.
- Funds reported $209M of Century Therapeutics stock for Q3 2022, up 14% quarter-over-quarter.
- 8 funds opened new Century Therapeutics positions in Q3 2022 and 10 closed out, a net change of -2 holders.
- The largest Century Therapeutics buyer in Q3 2022 was Avidity Partners Management, an estimated $4.62M added.
- The largest Century Therapeutics seller in Q3 2022 was RA Capital Management, an estimated $6.36M sold.
Based on aggregated 13F filings for Q3 2022.